Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530335 | 0.77 | INMT (0.30) | — | |
| SCHEMBL2552391 | 0.74 | GAA (0.40) | POLBGAA | |
| SCHEMBL13301040 | 0.60 | ACHE (0.47) | POLBGAA | |
| SCHEMBL1583262 | 0.60 | CHRM2 (0.40) | POLBGAA | |
| SCHEMBL3655855 | 0.58 | POLB (0.83) | POLBGAA | |
| SCHEMBL18322285 | 0.57 | PKM (0.35) | — | |
| SCHEMBL18322250 | 0.57 | PKM (0.35) | — | |
| SCHEMBL23236621 | 0.56 | POLB (0.57) | POLBGAA | |
| SCHEMBL15877734 | 0.56 | POLB (0.57) | POLBGAA | |
| SCHEMBL15878151 | 0.56 | POLB (0.57) | POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| EP-2552923-B1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R & D IRELAND (IE) | 2014-03-26 | — | — | EP | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| EP-2552923-A1 | MACROCYCLIC INTEGRASE INHIBITORS | Janssen R&D Ireland (IE) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011121105-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TYMP, PIM1, TYMS | POLB 27/4885GAA 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.